Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-label Study of Quadrivalent TAK-850 in Healthy Adults
jRCT2080223134Phase 2
- Sponsor
- Takeda
- Start
- Mar 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of TAK-850 in influenza, sponsored by Takeda. Primary endpoints: Safety of single-dose quadrivalent TAK-850 and Immunogenicity of single-dose quadrivalent TAK-850.
02
Drugs
TAK-850
03
Conditions
influenza
Beyond the preview
Go deeper on jRCT2080223134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223134.